Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder: A randomized, open-label, 12-week, parallel-group trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, Changsu | - |
dc.contributor.author | Pae, Chi-Un | - |
dc.contributor.author | Lee, Bun Hee | - |
dc.contributor.author | Ko, Young-Hoon | - |
dc.contributor.author | Masand, Prakash S. | - |
dc.contributor.author | Patkar, Ashwin A. | - |
dc.contributor.author | Jung, In-Kwa | - |
dc.date.accessioned | 2021-09-09T11:10:11Z | - |
dc.date.available | 2021-09-09T11:10:11Z | - |
dc.date.created | 2021-06-10 | - |
dc.date.issued | 2008-02-15 | - |
dc.identifier.issn | 0278-5846 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/124074 | - |
dc.description.abstract | The present study was conducted to compare the effectiveness and tolerability of fluoxetine and sertraline in the treatment of undifferentiated somatoform disorder (USD), using the Patient Health Questionnaire (PHQ-15), which was specifically designed for assessing the severity of somatic symptoms. A randomized, 12-week, open-label trial of fluoxetine (10-60 mg/d) and sertraline (25-350 mg/d) in patients with USD was conducted. Six visits, at baseline and weeks 1, 2, 4, 8, and 12, were scheduled. Assessments for effectiveness and tolerability were conducted at each visit. The primary effectiveness measure was the mean change in PHQ-15 total score, from baseline to the end of treatment. Secondary effectiveness measures were the mean changes in total scores on the Beck Depression Inventory (BDI) and the 12-item General Health Questionnaire (GHQ-12), from baseline to the end of treatment. A total of 45 subjects were enrolled; of them, 28 were randomly assigned to receive fluoxetine and 17 to receive sertraline. The total score on the PHQ-15 from baseline to the end of treatment significantly decreased in the fluoxetine (- 10.7, p<0.0001) and sertraline (- 10.3, p<0.0001) treatment groups, with no between-group difference (F=0.0701, p=0.7924). Overall, both treatments were well tolerated and no serious adverse event was reported. This study suggests that both agents may have a potential role in the treatment of USD. A double-blind, placebo-controlled trial and/or head-to-head comparison study with larger samples are required to draw more definite conclusions. (c) 2007 Elsevier Inc. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.subject | ST-JOHNS-WORT | - |
dc.subject | PRIMARY-CARE | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | REUPTAKE INHIBITORS | - |
dc.subject | PAIN DISORDER | - |
dc.subject | ANTIDEPRESSANTS | - |
dc.subject | EFFICACY | - |
dc.subject | ANXIETY | - |
dc.subject | PREVALENCE | - |
dc.subject | SYMPTOMS | - |
dc.title | Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder: A randomized, open-label, 12-week, parallel-group trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Han, Changsu | - |
dc.contributor.affiliatedAuthor | Ko, Young-Hoon | - |
dc.identifier.doi | 10.1016/j.pnpbp.2007.09.014 | - |
dc.identifier.scopusid | 2-s2.0-38749088722 | - |
dc.identifier.wosid | 000253847000017 | - |
dc.identifier.bibliographicCitation | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, v.32, no.2, pp.437 - 444 | - |
dc.relation.isPartOf | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | - |
dc.citation.title | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | - |
dc.citation.volume | 32 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 437 | - |
dc.citation.endPage | 444 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.subject.keywordPlus | ST-JOHNS-WORT | - |
dc.subject.keywordPlus | PRIMARY-CARE | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | REUPTAKE INHIBITORS | - |
dc.subject.keywordPlus | PAIN DISORDER | - |
dc.subject.keywordPlus | ANTIDEPRESSANTS | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | ANXIETY | - |
dc.subject.keywordPlus | PREVALENCE | - |
dc.subject.keywordPlus | SYMPTOMS | - |
dc.subject.keywordAuthor | Fluoxetine | - |
dc.subject.keywordAuthor | open-label | - |
dc.subject.keywordAuthor | Patient Health Questionnaire | - |
dc.subject.keywordAuthor | sertraline | - |
dc.subject.keywordAuthor | undifferentiated somatoform disorder | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.